Termination for Safety. Upon reasonable notice to Residents, University Housing may terminate Residents’ Residence Hall contracts to reduce the health risks associated with COVID-19 or other health risks. Termination of contracts may be necessary to further reduce residential density in the Residence Halls, to expand emergency housing capacity, due to inability to find alternative housing for Residents who need relocation, to close one or all of the Residence Halls, or to take other actions in the interest of public health and safety. If, at any time, the University closes the Residence Halls and requires all Residents to leave campus for the remainder of the academic year, Residents will not be charged for the remaining, canceled portion of the Residence Hall contract period.
Termination for Safety. Subject to Section 11.6, Fujisawa may terminate this Agreement in whole or in part (i.e., with respect to a particular Licensed Product and/or indication) at any time upon thirty (30) days prior written notice if: Fujisawa determines that there are safety concerns regarding the Licensed Products such that no Licensed Product could reasonably be developed that would meet Fujisawa's standards for product safety, so long as such determination is made in good faith and that Fujisawa applies the same standards to evaluate the safety of Licensed Products as it typically and customarily would apply for the safety evaluation of other products, including products derived from its own research and development efforts, at similar stages of development. In the event Fujisawa terminates under this Section 11.4(a), it would not owe any milestone payment that became due during the thirty (30) day notice period, or any other monies hereunder with respect to the terminated Licensed Product and/or indication, except for Milestone (2) under Section 5.3(b) in accordance with the terms thereof, where such termination occurred after the dosing of the last patient in the Phase I Trial.
Termination for Safety. Xxxxxxx may terminate this Agreement in the event the Licensed Component or Licensed Product Developed hereunder poses a serious safety issue.
Termination for Safety. 12.2.5.(a) Servier may terminate this Agreement with respect to (a) the Lead Product or (b) any Collaboration Product, CoDev Collaboration Product or Servier WW Collaboration Product, immediately upon written notice to Pieris, that such Product reasonably demonstrates a safety issue in humans.
Termination for Safety. Upon reasonable notice to Residents, University Housing may terminate Residents’ Graduate Village contracts to reduce the health risks associated with COVID-19 or other health risks. Termination of contracts may be necessary to further reduce residential density in Graduate Village, to expand emergency housing capacity, due to inability to find alternative housing for Residents who need relocation, to close Graduate Village in part or entirely, or to take other actions in the interest of public health and safety. If, at any time, the University closes Graduate Village pursuant to this paragraph and requires all Residents to leave campus for the remainder of the academic year, Residents will not be charged for the remaining, canceled portion of the Graduate Village contract period.
Termination for Safety. Notwithstanding anything to the contrary herein, following discovery of a Material Safety Issue, either Party may, upon written notice to the other Party, halt its ongoing Co-Exploited Product Development and Commercialization activities, investigate the Material Safety Issue, and determine a course of action. Following such investigation, such Party may elect to terminate the Co-Exploitation, and if such Party makes such election, then it shall provide written notice to the other Party of such termination and such termination shall take effect immediately. Within [***] days of discovery of a Material Safety Issue, the discovering Party must either elect to terminate the Co-Exploitation, or restart its Co-Exploitation, Development and Commercialization activities and thereafter conduct such activities in accordance with the Co-Exploitation Terms.
Termination for Safety. Takeda may terminate this Agreement in its entirety or with respect to a particular Product upon [***] ([***]) [***] prior written notice to ITI (a) if senior executives responsible for Takeda’s Pharmacovigilance and Clinical Science functions determine in good faith that the risk/benefit profile of such Product(s) is such that the Product(s) cannot continue to be Developed or administered to subjects/patients safely (and not for commercial reasons), or (b) upon the occurrence of serious adverse events related to the use of such Product(s) that cause Takeda to reasonably conclude that the continued use of such Product(s) by subjects/patients will result in subjects/patients being exposed to a product whose risks outweigh its benefits. Following notice of termination under this Section 13.5, the Parties shall cooperate to wind down all Development and Commercialization activities with respect to the terminated Product(s).
Termination for Safety. 16.2.6.1. SGEN may terminate this Agreement with respect to a Collaboration Product (other than a CoDev Product) immediately upon written notice to PIRS, that such Collaboration Product demonstrates a Safety Issue in humans.
Termination for Safety. If during the development or Commercialization of the Product, the Product becomes subject to a pattern of Serious Adverse Drug Experiences (as defined below) or either Party receives notice from a Regulatory Authority, independent review committee, data safety monitoring board or another similar Clinical Trial or post-marketing monitoring body alleging significant concern regarding a patient safety issue, in each case which NYCOMED, in good faith, reasonably believes would seriously impact the long-term viability of the Product, NYCOMED shall have the right to terminate its rights and obligations under this Agreement upon [* * *] written notice so long as NYCOMED reasonably believes the patient safety issue would seriously impact the long-term viability of the Product in the Territory. For purposes of this Agreement, a “Serious Adverse Drug Experience” means any adverse drug experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a Serious Adverse Drug Experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
Termination for Safety. Eff~xxxx Reasons. During the Term, until Xxxxxx obtains FDA approval of Product, Xxxxxx shall have the right to terminate this Agreement by providing Rubicon with ninety (90) days prior written notice in the event Xxxxxx determines that Product has adverse safety and/or efficacy problems that render continuation hereunder commercially unacceptable. Upon termination under this Section 14.4, Xxxxxx shall grant to Rubicon a worldwide, royalty-free, co-exclusive license (with sublicensing rights but without Xxxxxx retaining a right to license) to all improvements to Product that have been assigned to Xxxxxx pursuant to Section 2.2 and a world-wide, royalty free, non-exclusive license to the Xxxxxx Know-how. In no event shall Xxxxxx be required to pay Rubicon the milestone payments under Sections 8.2(a) and/or (b) in the event of a termination under this Section 14.4 unless such milestone payment is then or becomes payable in accordance with Section 8.2(a) of (b), as applicable, prior to the effective date of such termination. 14.5
